目的：观察外周血单个核细胞(PBMC)体外经IFN-γ， rIL-2和anti-CD3McAb诱导后细胞表型的变化及CIK细胞对裸鼠肝癌移植瘤的抑制作用。方法：采用成份血采血机采集6例健康自愿者PBMC，经多因子诱导后，计数活细胞数，流式细胞仪检测细胞表型；裸鼠肩胛下接种肝癌细胞，次日起连续6 d给予不同数量的CIK细胞，观察对肝癌生长的抑制作用。结果：诱导培养后13 d，效应细胞增殖7.1倍，CD3+CD56+双阳性细胞增殖约6倍。动物实验结果表明，CIK细胞可明显抑制肝癌移植瘤的生长，且肿瘤抑制率与CIK细胞的数量呈剂量效应关系。结论：PBMC细胞体外经多因子诱导成CIK细胞，其数量及抗肿瘤活性显著增加，对肝癌细胞的生长具有明显的抑制作用。

Objective: To investigate the inhibitory effects of the cytokine-induced killer (CIK) cells from human peripheral blood mononuclear cells (PBMCs) origin on the growth of hepatocellular carcinoma (HCC) cells in animal model. Methods: PBMCs from healthy donors were enriched by using the specific program of the Cobe Spectra blood separator and induced in vitro into CIK cells in serum-free culture medium containing interferon-gamma (IFN-γ), interleukin-2 (IL-2)，and anti-CD3. The phenotypes and characterization of CIK cells were identified by flow cytometric analysis. BALB/c nude mice subscapularly transplanted with 1.5×105 of BEL-7402 HCC cell at the exponential growth produced 100% tumor incidence and were treated with human CIK cells for consecutive six days on the second day after HCC transplantation. Results:The CIK cells identified by flow cytometric analyses were shown to be a heterogeneous population with different cellular phenotypes. The total CIK cells and CD3+/CD56+ positive cells significantly increased by 7 fold and 6-fold, respectively, in cell proliferation number at day 13 incubation, which suggested that the CD3+ CD56+ positive cells proliferated faster than other cell populations of CIK cells. In tumor-bearing nude mice, human CIK cells showed a significant inhibitory effect on the growth of transplanted HCC, resulting in a statistical significant difference among the treated and control groups. There was dose-response dependent relationship between the inhibitory effect and number of treated CIK cells. Conclusion: Human CIK cells are of highly efficient cytotoxic effector cells against hepatocellular carcinoma cells in murine model and are likely to be used as an immune therapeutic strategy for HCC patients